PROSPER Trial
The pragmatic RCT design, embedded within routine NHS pathways, enhances generalisability and real-world relevance. The trial is powered to detect a 3-point difference on the PHQ-9, representing the Minimally Clinically Important Differenc…
1 sources - 7 claims
The pragmatic RCT design, embedded within routine NHS pathways, enhances generalisability and real-world relevance. The trial is powered to detect a 3-point difference on the PHQ-9, representing the Minimally Clinically Important Difference. The absence of detailed oncology data as baseline variables limits subgroup interpretation but will inform future trial design. The primary outcome is change in depression severity measured by the PHQ-9 across four follow-up time points at 4, 8, 12, and 24 weeks post-randomisation.